Several studies have been performed and published.  A phase II study (Templeton et al., 2011) investigating the activity of everolimus 10mg/daily as first-line treatment found that in 37 enrolled patients, 12 (32%) remained progression-free at 12weeks. Other phase II studies of everolimus, alone or in combination with bicalutamide, bevacizumab, or chemotherapy, as well as trials testing other mTOR inhibitors such as temsirolimus and ridaforolimus, are currently recruiting patients.  More studies are awaited.

For Professional version see here

Several studies have found activity for Taxotere and carboplatin combinations.

The recent review of various taxane combination by Oh et al concluded: “More recent Phase II studies of carboplatin suggested a moderate level of clinical and palliative activity when it was used as a single agent. However, when carboplatin was combined with a taxane and estramustine, high response rates were observed in several recent clinical trials. ….Several preliminary reports suggested that carboplatin and oxaliplatin may have activity as second-line chemotherapy. Platinum chemotherapy drugs historically have been considered inactive in HRPC, although a review of the data suggested otherwise. Carboplatin, in particular, induced very high response rates when it was combined with estramustine and a taxane, but it also appeared to have activity in patients who progressed after docetaxel.”

Read the Professional version here.